Discover the Sun Pharma Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

Stay informed with the Sun Pharma Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of ...

Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...

Leading brokerage firm Emkay Research has maintained a bullish stance on Sun Pharma, assigning a ‘BUY’ rating with a price ...

Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Sun Pharma surges 3% on Checkpoint Therapeutics acquisition; Motilal Oswal maintains 'Buy' with 22% upside potential. Read ...

Sun Pharma share price today reached ₹1,651.80, a 2.50% rise from its last close of ₹1,611.50. The rise is despite the ...

Sun Pharma will pay an upfront cash payment of $4.1 per share, which amounts to an aggregate consideration of $355 million.

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

India-based Sun Pharmaceutical Industries Limited agreed to acquire U.S.-based immunotherapy and targeted oncology company ...

Sun Pharmaceutical has agreed to acquire Checkpoint Therapeutics for an aggregate consideration of up to $355m upfront.